Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | FER | P16591 | 1/20 | 0.32 |
| ▸ | LTK | P29376 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | CDC25B | P30305 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10708199 | 0.71 | GSK3B (0.38) | GSK3BLMNAMAPTCASP3CASP2 | |
| SCHEMBL10708204 | 0.71 | GSK3B (0.38) | GSK3BLMNAMAPTCASP3CASP2 | |
| SCHEMBL451291 | 0.70 | GRK6 (0.32) | MAPTGAA | |
| SCHEMBL223037 | 0.68 | CDC25B (0.50) | GSK3BLMNAMAPTCASP7MAOA | |
| SCHEMBL25254110 | 0.68 | CDC25B (0.50) | GSK3BLMNAMAPTCASP7MAOA | |
| SCHEMBL209273 | 0.68 | KDM4E (0.46) | GSK3BLMNAMAPTCASP3CASP2 | |
| SCHEMBL1096641 | 0.68 | MAOA (0.36) | GSK3BLMNAMAPTMAOALRRK2 | |
| SCHEMBL554699 | 0.66 | — | — | |
| SCHEMBL168935 | 0.66 | PDGFRA (0.52) | GSK3BCASP3CASP2CASP7CASP6 | |
| SCHEMBL20504712 | 0.66 | GSK3B (0.44) | GSK3BLMNAMAPTCASP3CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049472-B1 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2015-01-21 | — | — | EP | claimed |
| US-8829041-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2014-09-09 | — | — | US | claimed |
| EP-2049472-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | Abbott Laboratories (US) | 2009-04-22 | — | — | EP | claimed |
| US-20080242653-A1 | Cyclopropyl amine derivatives | ABBVIE INC. | 2008-10-02 | — | — | US | claimed |
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | ABBVIE INC. | 2008-01-24 | — | — | US | claimed |
| WO-2007150010-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | claimed |
| US-9108948-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2049472-B1 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2015-01-21 | — | — | EP | disclosed |
| US-8829041-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8580968-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153813-B2 | Benzothiazole and benzooxazole derivatives and methods of use | ABBOTT LABORATORIES (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2237779-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | Abbott Laboratories (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009085945-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080242653-A1 | Cyclopropyl amine derivatives | ABBVIE INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | ABBVIE INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | HRH4, HRH3, HNMT | GSK3B 2143/4885LMNA 4566/4885MAPT 178/4885 |
| US-20080242653-A1 | Cyclopropyl amine derivatives | HRH3, HRH4, HRH2 | GSK3B 3697/4885LMNA 3484/4885MAPT 2179/4885 |
| US-20120164070-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | HRH2, HRH1, HRH4 | GSK3B 4160/4885LMNA 3397/4885MAPT 2328/4885 |
| US-20090163464-A1 | BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE | HRH2, HRH1, HRH4 | GSK3B 4160/4885LMNA 3397/4885MAPT 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.